Piper Sandler analyst Matthew O'Brien maintains $TransMedics (TMDX.US)$ with a buy rating, and maintains the target price at $180.
According to TipRanks data, the analyst has a success rate of 49.5% and a total average return of 4.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $TransMedics (TMDX.US)$'s main analysts recently are as follows:
TransMedics' third-quarter results fell short of expectations, and while the management has upheld its guidance for FY24, it suggests a broad spectrum of growth possibilities for the fourth quarter. Despite a sequential dip in transplant volumes across all three organ categories, the company maintains that it has not conceded any market share during the quarter. Analysts perceive the company as a dominant player in a market that remains largely untapped.
While there was an anticipation of a more subdued upside in Q3 for TransMedics, the actual performance shortfall was unexpected. Despite this, the company achieved significant growth of +64% and maintained its guidance for FY24. The challenges faced are seen as temporary and are not a result of market share loss or pricing pressure related to OCS disposables.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
